H.b. Fuller Licensing & Financing Inc.

Medtronic, Inc.

Triton Biosystems, Inc.

Douglas Ulen Gwost

Youlu Duan

Sonja E Stammler

Muthiah Manoharan

William Frederick Kaemmerer

Andrei P Guzaev

Brian Dale Nelson

Erik Schroeder Handy

Matthew H Adams

Peter A Voss

Diane L Ellis-Busby

Thomas E Rolando

David Kent Stiles

Yuduo Zhu

Yi Wei

Michael J Maksymkiw

Lowell G Lindquist

Susan J Braunhut

Allan Foreman

Scott W Rhein

Robert Ivkov

Pei Ge

Gregory Robert Stewart

Don Marshall Gash

Dinah W Y Sah

Michael J Dockniak

Blair Ardman

This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.

Treatment of neurological disorders

Disclosed are therapeutic methods for the treatment of disease material involving administration of a thermotherapeutic magnetic composition, which contains single-domain magnetic particles attached to a target-specific ligand, to a patient and application of an alternating magnetic field to inductively heat the thermotherapeutic magnetic composition. Also disclosed are methods of administering the thermotherapeutic magnetic material composition. The thermotherapeutic methods may be used where the predetermined target is associated with diseases, such as cancer, diseases of the immune system, and pathogen-borne diseases, and undesirable targets, such as toxins, reactions associated with organ transplants, hormone-related diseases, and non-cancerous diseased cells or tissue.

Thermotherapy via targeted delivery of nanoscale magnetic particles

The present invention is directed to aqueous polyurethane dispersions and aqueous polyurethane-acrylic dispersions, especially polymer dispersions formed from norbornane diisocyanate. The dispersions, and the dried polymers therefrom, are useful adhesives that provide enhanced bond strength when subjected to increased thermal and mechanical stress. Additionally, the inventive dispersions form polymers having increased adhesion compared to similar polymers based on cycloaliphatic diisocyanates which are free of a methylene bridge.

Aqueous polyurethane dispersions formed from polyisocyanates having a

A process for the preparation of sulfonated polyurethane-urea polymers, which are useful film to film laminating adhesives for flexible packaging in which the urethane-urea polymer component has no amide linkages. The water-based sulfonated polyurethane prepolymers are processed at reduced temperatures and are substantially free of volatile and/or leachable contaminants.

Laminating adhesives for flexible packaging

Growing community of inventors

Shoreview, MN, United States of America

Douglas Ulen Gwost